FCHSD2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited suspension culture of Raji Burkitt lymphoma B lymphocytes with targeted disruption of the FCHSD2 gene. This polyclonal knockout pool provides a loss-of-function model to study FCHSD2-dependent actin cytoskeleton dynamics and invadopodia formation in a B-cell lymphoma context, avoiding biases of single-cell clones.
The parental Raji cell line, derived from a patient with EBV-positive Burkitt lymphoma, grows in suspension and displays activated B-cell characteristics. Its well-characterized signaling and robust proliferation make it an established model for lymphomagenesis and EBV-host interactions.
FCHSD2 is an adaptor protein linking Cdc42 and Rac1 signals to actin polymerization. It recruits WASL (N-WASP) and cortactin to the ARP2/3 complex, driving branched actin assembly and invadopodia formation essential for cell migration and invasion. Physical interactions with WIPF1 and actin further stabilize these protrusive structures.
In Burkitt lymphoma, invasion potential contributes to disease dissemination. This knockout model enables dissection of FCHSD2’s role in B-cell lymphoma migration and EBV-related pathology, serving as a tool to explore actin-driven metastatic mechanisms and identify therapeutic targets.
Applications include Transwell migration/invasion assays, immunofluorescence for invadopodia (F-actin, cortactin), co-immunoprecipitation of interacting partners, and phospho-signaling studies. The cells support drug screening for metastasis inhibitors, RNA-seq for transcriptional profiling, and validation via qPCR/Western blot of downstream factors like WASL and CTTN. For assistance, contact Ascent Research.
